BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
BBOT Stock Chart & Stats
$12.59
--
Market closed
$12.59
--
Day’s Range― - ―
52-Week Range$8.50 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$710.69M
Enterprise Value$339.77M
Total Cash (Recent Filing)$425.46M
Total Debt (Recent Filing)$2.77M
Price to Earnings (P/E)―
Beta0.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,032,820
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.75K
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$25.38Price Target Upside101.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Pipeline Value DriversAnalyst points to substantial cash reserves and multiple planned clinical readouts and combination studies across the pipeline as potential value inflection points that support continued development and valuation upside.
Clinical Efficacy And Combination PotentialAnalyst notes that BBO-8520 showed strong tumor response rates as monotherapy and produced responses when combined with pembrolizumab across tumor PD-L1 expression levels, suggesting potential for first-line or combination regimens.
Safety ProfileAnalyst highlights that BBO-8520's favorable safety profile, with no observed liver enzyme elevations or heart rhythm prolongation in trials, could enable broader combination use without adding significant toxicity concerns.
Bears Say
Clinical And Regulatory RiskAnalyst warns that clinical setbacks or failure to advance assets into pivotal trials could lead to regulatory rejection and materially affect the company's development trajectory.
Commercialization And Equity Dilution RiskAnalyst highlights risks around commercialization challenges and potential equity dilution that could weigh on the stock if development timelines or market access prove more difficult than expected.
Key Opinion Leader Skepticism On TolerabilityAnalyst cautions that skepticism among key opinion leaders about tolerability of earlier inhibitor classes means the company must demonstrate durable safety in combination settings before broader clinical adoption is likely.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $8.50 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $710.69M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
Currently, no data Available
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,032,820 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.38 (101.55% Upside)
$25.38 (101.55% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
-65.52%
Trailing 12-Months
Asset Growth
130.98%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
BBOT Stock 12 Month Forecast
Average Price Target
$25.38
▲(101.55% Upside)